Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

669 results about "Sense strand" patented technology

In genetics, a sense strand, or coding strand, is the segment within double-stranded DNA that runs from 5' to 3', and which is complementary to the antisense strand of DNA, or template strand, which runs from 3' to 5'. The sense strand is the strand of DNA that has the same sequence as the mRNA, which takes the antisense strand as its template during transcription, and eventually undergoes (typically, not always) translation into a protein. The antisense strand is thus responsible for the RNA that is later translated to protein, while the sense strand possesses a nearly identical makeup to that of the mRNA. Note that for each segment of dsDNA, there will possibly be two sets of sense and antisense, depending on which direction one reads (since sense and antisense is relative to perspective). It is ultimately the gene product, or mRNA, that dictates which strand of one segment of dsDNA we call sense or antisense. But keep in mind that sometimes, such as in prokaryotes, overlapping genes on opposite strands means the sense for one mRNA can be the antisense for another mRNA.

Modification template for improving inhibitory effect of double-stranded oligonucleotide on target gene, combination thereof and use thereof

A modification template for improving the inhibitory effect of a double-stranded oligonucleotide on a target gene, a combination thereof and the use thereof. The double-stranded oligonucleotide is an siRNA and contains a sense strand and an antisense strand, and each nucleotide of the sense strand and antisense strand is a modified nucleotide. The double-stranded oligonucleotide is modified with a special modification template, and has a significantly improved inhibition rate on a target gene compared with a basic sequence.
Owner:HANGZHOU TIANLONG PHARM CO LTD

Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof

Provided are siRNA for inhibiting an expression level of a RPTOR gene and regulating and controlling the activity of mTORC1, and a pharmaceutical composition and conjugate containing the siRNA. The siRNA includes a sense strand and an antisense strand; each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The sense strand includes a nucleotide sequence I, the length of the nucleotide sequence I is equal to the length of a nucleotide sequence as shown in SEQ ID NO: 1, with no more than three nucleotide differences; the antisense strand includes a nucleotide sequence II, the length of the nucleotide sequence II is equal to the length of a nucleotide sequence as shown in SEQ ID NO: 2, with no more than three nucleotide differences.
Owner:SUZHOU RIBO LIFE SCIENCE CO LTD

Pharmaceutical composition and application thereof

The present invention discloses a pharmaceutical composition comprising a circular RNA and a drug delivery carrier. Compared with traditional linear 1 * siRNA and annular 1 * siRNA, the number of repeated series connection of positive-sense strands is increased to include but not limited to two or more, it is accidentally found that the silence effect is remarkably enhanced, the expression level of the PCSK9 gene can be remarkably reduced, and degradation of mRNA of PCSK9 protein is mediated. The nano-particles are used for delivering oligonucleotide, so that the stability is improved, the immunogenicity is reduced, the effects of lowering cholesterol, reducing aortic plaque load and resisting atherosclerosis are improved, and the nano-particles are safe and free of obvious liver and kidney toxicity and have a wide application prospect in the aspect of preparing medicines for treating hypercholesterolemia and coronary heart disease.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Modified template for improving inhibition effect of double-stranded oligonucleotide target gene as well as combination and application of modified template

The invention discloses a modification template for improving the target gene inhibition effect of double-stranded oligonucleotide and a combination and application of the modification template, the double-stranded oligonucleotide is siRNA and contains a positive-sense strand and an antisense strand, and each nucleotide of the positive-sense strand and the antisense strand is a modified nucleotide. The double-stranded oligonucleotide is modified by a special modification template, and compared with a basic sequence, the inhibition rate of the double-stranded oligonucleotide to a target gene is remarkably improved.
Owner:HANGZHOU TIANLONG PHARM CO LTD

Circular multimeric tandem RNA sense strand

Provided is a circular multimeric tandem RNA sense strand, comprising at least one sense strand sequence and at least one spacer sequence. The circular RNA is derived from an engineered parental DNA template containing all essential sequences, and sequentially comprises a first cyclization element, optionally at least one first restriction enzyme recognition sequence, at least one target sequence, optionally at least one second restriction enzyme recognition sequence, and a second cyclization element. The circular multimeric tandem RNA sense strand can bind and deliver a plurality of antisense strand RNA, increasing the binding of the sense strand and the antisense strand while utilizing the stability advantage of circular RNA.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Sirna molecule for inhibiting PCSK9 expression and use thereof

Relating to the technical field of gene therapy, provided is an siRNA molecule for inhibiting PCSK9 expression, and use thereof. Particularly, an siRNA molecule for inhibiting PCSK9 expression (comprising a sense strand and an anti-sense strand that are complementary to form a double-stranded region) and a pharmaceutical composition comprising the same are disclosed. The siRNA molecule has a high silencing efficiency and a long-lasting silencing effect for PCSK9 gene, and is useful in the manufacture of products for inhibiting PCSK9 protein expression, products for reducing the concentration of low-density lipoprotein or low-density lipoprotein cholesterol in serum; and products for relieving the symptoms of PCSK9 gene-mediated diseases.
Owner:HANGZHOU DINOVATE BIOTECH CO LTD

Inhbe gene-targeted double-stranded oligonucleotide, conjugate, composition and use thereof

Provided are an INHBE gene-targeted double-stranded oligonucleotide, a conjugate, and a composition, which relate to the technical field of nucleic acid drugs. The double-stranded oligonucleotide comprises a sense strand and an antisense strand. The antisense strand is complementary or substantially complementary to the sense strand; the sense strand comprises a nucleotide sequence identical or substantially identical to at least 15 consecutive nucleotides in a sequence of SEQ ID NO: 309, and said substantially identical means that there is no more than three nucleotide differences between the sense strand and the at least 15 consecutive nucleotides in the sequence of SEQ ID NO: 309. The double-stranded oligonucleotide can effectively inhibit the INHBE gene and treat patients suffering from metabolic diseases or metabolic syndrome and related diseases such as diabetes, hypertension and cardiovascular diseases.
Owner:RIGERNA THERAPEUTICS (SUZHOU) CO LTD

Annular multi-series PCSK9 siRNA

The invention provides annular multi-tandem PCSK9 siRNA, which comprises at least one positive-sense strand sequence and at least one spacer sequence. The sense strand of the cyclic siRNA is derived from an engineered parent DNA template containing all essential sequences, comprising in the following order a first cyclization element, optionally at least one first restriction enzyme recognition sequence, at least one target sequence, optionally at least one second restriction enzyme recognition sequence, and a second cyclization element. The annular multi-tandem RNA positive-sense strand can combine and deliver a plurality of antisense strand RNAs, and the combination of the positive-sense strand and the antisense strand is increased while the stability advantage of the annular RNA is utilized.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Dual silencing

PendingGB2635479AOrganic active ingredientsSpecial deliveryProprotein Convertase Subtilisin/Kexin 9Single strand
A nucleic acid molecule comprising: i) a first nucleic acid comprising a double stranded inhibitory ribonucleic acid (RNA) molecule comprising a sense and an antisense strand designed with reference to a nucleotide sequence comprising a cardiovascular disease associated gene to be silenced and wherein said cardiovascular gene is proprotein convertase subtilisin kexin 9 (PCSK9) there is provided a single stranded deoxyribonucleic acid (DNA) molecule conjugated to the 5’ end of said sense strand; and ii) a second nucleic acid comprising a double stranded inhibitory ribonucleic acid (RNA) molecule comprising a sense and an antisense strand designed with reference to a different cardiovascular disease associated gene to be silenced wherein said cardiovascular gene is lipoprotein (a) (Lp(a)) and wherein there is provided a single stranded deoxyribonucleic acid (DNA) molecule conjugated to the 5’ end of said sense strand wherein the single stranded deoxyribonucleic acid (DNA) molecule is substantially complementary to the single stranded deoxyribonucleic acid (DNA) molecule set forth in i) above and anneals by complementary base pairing to form a double stranded DNA linker that links the first and second double stranded inhibitory ribonucleic acid (RNA) molecules.
Owner:ARGONAUTE RNA LTD

Pharmaceutical composition and use thereof

Provided is a pharmaceutical composition, comprising a circular RNA and a drug delivery carrier. It is surprisingly found that compared with conventional linear 1 x siRNAs and circular 1 x siRNAs, increasing the number of tandem repeats in the sense strand to two or more significantly enhances the silencing effect, significantly reduces the expression level of the PCSK9 gene, and mediates the degradation of the PCSK9 protein mRNA. The use of nano-particles for delivering oligonucleotides features improved stability, reduced immunogenicity, improved cholesterol-lowering, aortic plaque load-reducing and anti-atherosclerotic effects, good safety, no significant liver and kidney toxicity, and therefore good prospects in preparing medicaments for treating hypercholesterolemia and a coronary heart disease.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Circular concatemeric PCSK9 sirna

Provided is a circular concatemeric PCSK9 siRNA, comprising at least one sense strand sequence and at least one spacer sequence. The sense strand of the circular siRNA is derived from an engineered parental DNA template containing all essential sequences, which comprises, in the following order: a first cyclization element, optionally at least one first restriction enzyme recognition sequence, at least one target sequence, optionally at least one second restriction enzyme recognition sequence, and a second cyclization element. The sense strand of the circular concatemeric RNA can bind and deliver a plurality of antisense strand RNAs, enhancing the binding between the sense and antisense strands while leveraging the stability advantage of the circular RNA.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Application of non-therapeutic-purpose GLYR1 protein in regulating and controlling proliferation and / or migration of renal clear cell carcinoma cells

ActiveCN119265239Afacilitate early diagnosisgood treatment effectNucleic acid vectorOxidoreductasesClear cellEfficacy
The invention discloses an application of non-therapeutic GLYR1 protein in regulating and controlling proliferation and / or migration of renal clear cell carcinoma cells, which is characterized in that the expression of GLYR1 is knocked down so as to promote the proliferation and / or migration of the renal clear cell carcinoma cells, a reagent adopted for knocking down the expression of the GLYR1 is si-GLYR1 # 1, a positive-sense strand of the si-GLYR1 # 1 is CGGUAGAUGCUGUCGAAGA, an antisense strand of the si-GLYR1 # 1 is UCUUCGACAGCAUCUACCG, the antisense strand of the si-GLYR1 # 1 is CGGUAGAUGCUGCAUCUACCG is The kit has the characteristics of high sensitivity, strong specificity, short period and the like, is beneficial to early diagnosis and treatment of the clear cell renal carcinoma, and has the potential of becoming a novel biomarker and an effective treatment target in the clear cell renal carcinoma.
Owner:NINGBO UNIV

SiRNA for targeted regulation of HBV gene expression and application thereof

The invention provides siRNA for targeted regulation and control of HBV gene expression and application of the siRNA. The double-stranded RNAi agent comprises an antisense strand and a sense strand complementary to the antisense strand forming a double-stranded region, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO: 8, or the nucleotide sequence of the antisense strand is a modified sequence of the sequence as shown in SEQ ID NO: 8. Cell and animal experiment results show that the double-stranded RNAi agent provided by the invention can significantly reduce the expression of one or more HBV genes and block the life cycle of viruses, and can be used for developing drugs for treating HBV gene expression related diseases.
Owner:HANGZHOU TIANLONG PHARM CO LTD

Sirna for inhibiting the gene expression of lftslp and composition thereof

Provided is a siRNA for inhibiting the gene expression of lfTSLP, said siRNA comprising a sense strand and an antisense strand. The provided siRNA can specifically target the long isoform of TSLP having pro-inflammatory activity, and inhibit the mRNA and protein expression of the long isoform of TSLP, while not affecting the mRNA and protein expression of the short isoform of TSLP having anti-inflammatory activity. Therefore, the siRNA has important clinical value for the treatment of lfTSLP related diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Novel therapeutic DNA forms

PCT designated stage expiredWO2025096807A2DNA/RNA fragmentationNucleotideNucleobase
The disclosure provides, for example, a double stranded DNA (dsDNA) molecule comprising chemically modified nucleotides. In some embodiments, the dsDNA molecule comprises an upstream DNA end form which is a closed end, a downstream DNA end form which is a closed end, and a double stranded region comprising a sense strand and an antisense strand, in which the sense strand comprises one or more chemically modified nucleobases, and the antisense strand is free of chemically modified nucleobases.
Owner:FLAGSHIP PIONEERING INNOVATIONS VII LLC

ShRNA for knocking down BST2 gene expression, recombinant vector and application

The invention belongs to the technical field of gene engineering, and provides shRNA (short hairpin Ribonucleic Acid) for knocking down BST2 gene expression, a recombinant vector and application of the shRNA, and the shRNA comprises Bst2-shRNA-1 or Bst2-shRNA-2; the Bst2-shRNA-1 comprises a positive-sense strand of which the nucleotide sequence is as shown in SEQ ID NO. 1 and an antisense strand of which the nucleotide sequence is as shown in SEQ ID NO. 2; the Bst2-shRNA-2 comprises a positive-sense strand of which the nucleotide sequence is as shown in SEQ ID NO. 3 and an antisense strand of which the nucleotide sequence is as shown in SEQ ID NO. 4. The shRNA disclosed by the invention plays an important role in inhibiting non-infectious aseptic inflammation, can effectively delay the ALS attack time and protect motor neurons, has a very good application prospect, and also provides a direction and a technical basis for searching, researching and developing new therapeutic drugs for treating ALS.
Owner:CHIFENG MUNICIPAL HOSPITAL

Compositions and methods for accurately identifying mutations

The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.
Owner:FRED HUTCHINSON CANCER CENT

Chemically-modified oligonucleotide having rnai activity

There is provided an oligonucleotide or a pharmaceutically acceptable salt thereof with a novel chemical modification pattern, which has a RNA interfering action and / or a gene expression suppressing action. A sense strand region has a specific modification pattern with a 3'-modified nucleoside, and an antisense strand region has, in a specific region, a modification pattern in which DNA, RNA, 2'-O,4'-C-bridging-modified nucleosides, 2'-MOE RNA or the like are appropriately combined.
Owner:DAIICHI SANKYO CO LTD

Double-stranded oligonucleotide and use thereof in inhibiting expression of angiotensinogen

PCT designated stage expiredWO2025044868A1Organic active ingredientsSenses disorderNucleotideSense strand
A double-stranded oligonucleotide and a use thereof in inhibiting the expression of angiotensinogen (AGT). The double-stranded oligonucleotide comprises a sense strand and an antisense strand; the antisense strand contains a nucleotide sequence comprising at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 contiguous nucleotides of any sequence in SEQ ID NO: 225-SEQ ID NO: 448, or contains a nucleotide sequence which differs from the contiguous nucleotides by 1, 2, or 3 nucleotide(s).
Owner:RIGERNA THERAPEUTICS (SUZHOU) CO LTD

Sirna for inhibiting XDH gene expression and modifier and use thereof

Provided siRNA for inhibiting XDH gene expression and a modifier and use thereof. The siRNA comprises a sense strand and an antisense strand. The sense strand and / or the antisense strand have a length in the range of 19-25 nucleotides, and the antisense strand is reversely complementary to a segment on a target gene; and the sense strand has a nucleotide sequence as shown in SEQ ID NO: 1-14, and the antisense strand has a nucleotide sequence as shown in SEQ ID NO: 18-31. siRNA molecules and modified siRNA molecules have high stability and / or high inhibitory activity. Ligand-conjugated siRNA molecules have good liver targeting performance and the capability to promote cell endocytosis while maintaining high inhibitory activity and stability, can reduce the impact on other tissues or organs and reduce the amount of siRNA molecules used, and can achieve the purposes of reducing toxicity and reducing costs.
Owner:LIVZON PHARM GRP INC

SiRNA for treating androgenetic alopecia, nano preparation and preparation method thereof

The invention relates to siRNA for treating androgenetic alopecia, a nano preparation and a preparation method of the siRNA. The siRNA comprises a positive-sense strand and an antisense strand, the positive-sense strand is as shown in SEQ ID NO. 1, and the antisense strand is as shown in SEQ ID NO. 2. The siRNA disclosed by the invention can be used for efficiently and quickly inhibiting the expression of an androgen receptor in vivo and in vitro. When the medicine containing the siRNA is applied to the surface of the alopecia skin, the treatment effect can be quickly achieved, the hair growth speed is increased, and the hair regeneration time of the alopecia part is shorter.
Owner:SUN YAT SEN UNIV

Nucleic acid, composition and conjugate containing same, preparation method, and use thereof

The present disclosure provides a siRNA for inhibiting the expression of apolipoprotein C3 (ApoC3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.
Owner:SUZHOU RIBO LIFE SCIENCE CO LTD

SiRNA for inhibiting GPR75 gene expression and application thereof

The invention discloses siRNA for inhibiting GPR75 gene expression and application of the siRNA. The siRNA comprises a positive-sense strand and an antisense strand, and the antisense strand has a nucleotide sequence which is different from a nucleotide sequence shown in any one of SEQ ID NO.109-216 and SEQ ID NO.226-231 by not more than 3 nucleotides; the antisense strand and the positive-sense strand are at least partially complementary to form a double-strand region. The invention provides siRNA for inhibiting GPR75 gene expression, the siRNA is modified to ensure the stability and inhibitory activity of the siRNA, and experiments prove that multiple groups of siRNA have obvious inhibitory activity on GPR75 gene expression, and show application prospects in preparation of drugs for treating or preventing GPR75 expression related diseases in human bodies.
Owner:SUZHOU GENEPHARMA

Dsrna molecule for inhibiting LP(a) gene expression and use thereof

Disclosed are a modified dsRNA molecule and a use thereof. Specifically, provided is a dsRNA molecule for inhibiting LP(a) gene expression, comprising a sense strand and an antisense strand complementary to form a double-stranded region, wherein the sense strand and / or the antisense strand comprises 15-25 nucleotides or consists of 15-25 nucleotides. The dsRNA molecule can be used for treating and / or preventing LP(a) gene-mediated diseases.
Owner:CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD

CFB inhibitor composition and use thereof

PCT designated stage expiredWO2025026228A1Organic active ingredientsSpecial deliveryDiseaseNucleotide
The present invention relates to the technical field of nucleic acid drugs, and particularly provides a double-stranded oligonucleotide for inhibiting complement factor B (CFB) gene expression. The double-stranded oligonucleotide comprises a sense strand and an antisense strand; the sense strand contains at least fifteen consecutive nucleotides in any one sequence shown as SEQ ID NO: 1-SEQ ID NO: 255 in Table 1 or a nucleotide sequence which differs from the at least fifteen consecutive nucleotides in respect of not more than three nucleotides; and / or, the antisense strand contains at least fifteen consecutive nucleotides in any one sequence shown as SEQ ID NO: 256-SEQ ID NO: 510 in Table 1 or a nucleotide sequence which differs from the at least fifteen consecutive nucleotides in respect of not more than three nucleotides. The double-stranded oligonucleotide can inhibit CFB gene expression in cells, thereby achieving the effects of relieving, treating and / or preventing diseases or disorders mediated by abnormal CFB gene expression.
Owner:RIGERNA THERAPEUTICS (SUZHOU) CO LTD

siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2

Provided is novel siRNA having an RNA interfering action and / or a gene expression suppressing action on mRNA encoding TfR2, or the like. An oligonucleotide or a pharmaceutically acceptable salt thereof, or the like, has a knockdown action on mRNA of transferrin receptor 2, and consists of an antisense strand region containing a target-matching sequence substantially complementary to a target sequence in mRNA encoding TfR2, and a sense strand region containing a nucleotide sequence substantially complementary to the target-matching sequence of the antisense strand region.
Owner:DAIICHI SANKYO CO LTD

Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use

PCT designated stage expiredWO2025140402A1Organic active ingredientsSenses disorderBase JNucleotide
Provided is an siRNA for inhibiting the gene expression of complement factor B (CFB), or a pharmaceutical composition or conjugate containing the siRNA. The siRNA contains a sense strand and an antisense strand. Each nucleotide in the siRNA is an independent modified or unmodified nucleotide. The sense strand contains a segment of nucleotide sequence I, and the nucleotide sequence I and a nucleotide sequence show in SEQ ID NO: 1 have an equal length and differ by no more than 3 bases. The antisense strand contains a nucleotide sequence II, and the nucleotide sequence II and a nucleotide sequence shown in SEQ ID NO: 2 have an equal length and differ by no more than 3 bases. The siRNA or the pharmaceutical composition or conjugate containing the siRNA can effectively treat and / or prevent diseases related to the mRNA level of the gene expression of the CFB.
Owner:SUZHOU RIBO LIFE SCIENCE CO LTD

RNAi agents targeting LPA genes and uses thereof

Provided are an RNAi agent targeting a lipoprotein (a) (LPA) gene and a use thereof, and more particularly, an RNAi agent comprising an antisense strand having sequence complementarity with an LPA mRNA sequence and a sense strand having sequence complementarity with the antisense strand, and a pharmaceutical composition for preventing or treating cardiovascular diseases comprising the RNAi agent.
Owner:HANSOH (SHANGHAI) HEALTHTECH CO LTD +1

Sirna, sirna conjugate, pharmaceutical composition and use thereof

PCT designated stage expiredWO2025036511A1Cardiovascular disorderDNA/RNA fragmentationDiseaseNucleotide
An siRNA that inhibits the expression of the angiotensinogen (AGT) gene, an siRNA conjugate, a pharmaceutical composition and the use thereof. The siRNA contains a sense strand and an antisense strand, wherein the antisense strand contains at least 19 consecutive nucleotides that differ by no more than three nucleotides from any one of the antisense strand sequences as shown in table 1. Further provided is a method for preventing and / or treating diseases associated with angiotensinogen dysregulation using at least one of the siRNA, the siRNA conjugate, and the pharmaceutical composition.
Owner:CHENGDU GUOHONG PHARMA

SiRNA for inhibiting PLN gene expression and conjugate and application thereof

The invention belongs to the field of biological medicine, and relates to siRNA for inhibiting PLN gene expression and a conjugate, the siRNA comprises a positive-sense strand and an antisense strand, the positive-sense strand comprises a nucleotide sequence I, and the antisense strand comprises a nucleotide sequence II; each nucleotide in the nucleotide sequence I and the nucleotide sequence II is modified or unmodified nucleotide; the nucleotide sequence I and the nucleotide sequence II are at least partially reversely complementary to form a double-stranded region; the nucleotide sequence I is basically consistent with a first section of nucleotide sequence, and the first section of nucleotide sequence is a section of nucleotide sequence with the length of at least 19 nucleotides in mRNA expressed by the PLN gene. The siRNA and the conjugate and the pharmaceutical composition thereof disclosed by the invention can effectively prevent and / or treat diseases associated with PLN expression, such as heart failure, cardiomyopathy, arrhythmia and the like, and have a good patent medicine prospect.
Owner:BEIJING GLYEXO GENE TECH CO LTD